JMP Securities analyst Constantine Davides initiated coverage of Cross Country Healthcare with a Market Perform rating and no price target. The analyst is constructive on the long-term opportunity for Cross Country to benefit from recent technology investments as it looks to continue its evolution into a more holistic, tech-enabled provider of workforce solutions to healthcare organizations. However, the firm believes the company’s initiatives may take time to meaningfully impact growth and potential share gains.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CCRN:
- Cross Country Healthcare initiated with a Neutral at UBS
- Cross Country price target lowered to $26 from $29 at Barrington
- Cross Country Healthcare downgraded to Hold from Buy at Jefferies
- AMN Healthcare downgraded to Hold from Buy at Jefferies
- Cross Country Healthcare price target lowered to $24 from $31 at Benchmark
